W. Gillespie

发表

Linear systems approach to the analysis of an induced drug removal process. Phenobarbital removal by oral activated charcoal

M. J. Berg, P. Veng‐Pedersen, W. Gillespie, 1986, Journal of Pharmacokinetics and Biopharmaceutics.

Deconvolution applied to the kinetics of extracorporal drug removal. Haemodialysis of cefsulodin

P. Veng‐Pedersen, W. Gillespie, T. Gibson, 2004, European Journal of Clinical Pharmacology.

Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework

W. Gillespie, 1993, Journal of Pharmacokinetics and Biopharmaceutics.

Gastrointestinal bioavailability: determination of in vivo release profiles of solid oral dosage forms by deconvolution.

P. Veng‐Pedersen, W. Gillespie, 1985, Biopharmaceutics & drug disposition.

The mean residence time of drugs in the systemic circulation.

P. Veng‐Pedersen, W. Gillespie, 1985, Journal of pharmaceutical sciences.

Single pass mean residence time in peripheral tissues: a distribution parameter intrinsic to the tissue affinity of a drug.

P. Veng‐Pedersen, W. Gillespie, 1986, Journal of pharmaceutical sciences.

Mean residence time in peripheral tissue: A linear disposition parameter useful for evaluating a drug's tissue distribution

P. Veng‐Pedersen, W. Gillespie, 1984, Journal of Pharmacokinetics and Biopharmaceutics.

Chemical and enzymic ketonization of 2-hydroxymuconate, a conjugated enol

C. P. Whitman, N. Stolowich, W. Gillespie, 1991 .

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis

M. Gastonguay, M. Riggs, W. Gillespie, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates

Jin Y. Jin, S. Girish, B. Fine, 2019, CPT: pharmacometrics & systems pharmacology.

Clinical Pharmacology Studies in Patients with Renal Impairment: Past Experience and Regulatory Perspectives

Shiew-Mei Huang, L. Lesko, Roger L. Williams, 2000 .

Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results.

P. Welling, R. Patel, W. Craig, 1982, Journal of pharmaceutical sciences.

Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam.

D. Greenblatt, M. Divoll, W. Gillespie, 1983, Journal of clinical psychopharmacology.

Excretion of ibuprofen into breast milk.

J. Gschwend, T. Benedetti, K. Albert, 1984, American journal of obstetrics and gynecology.

Ibuprofen Kinetics In Plasma and Synovial Fluid of Arthritic Patients

D. Perrier, J. Gallo, K. Albert, 1986, Journal of clinical pharmacology.

Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations.

L. Lesko, P. Marroum, V. Shah, 1997, Advances in experimental medicine and biology.

Comparative Performance of Bayesian Markov Chain Monte Carlo and Maximum Likelihood Population Estimation Methods when Applied to Nonlinear Pharmacokinetics of Monoclonal Antibodies

B. Meibohm, J. Panetta, M. Gastonguay, 2010 .

Extension of a Multiscale Model of Calcium Homeostasis and Bone Remodeling to Include the Progressive Effects of Estrogen Loss During Menopause Transition.

M. Gastonguay, M. Riggs, M. Peterson, 2010 .

Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding

W. Gillespie, Haiyung Cheng, 1996, Journal of Pharmacokinetics and Biopharmaceutics.

Mean residence time concepts for non‐linear pharmacokinetic systems

W. Jusko, W. Gillespie, Haiyung Cheng, 1994, Biopharmaceutics & drug disposition.

Evaluation of Orally Administered Highly Variable Drugs and Drug Formulations

Mario A. González, W. H. Barr, L. Benet, 1996, Pharmaceutical Research.

Clinical Pharmacology Studies in Patients with Renal Impairment: Past Experience and Regulatory Perspectives

Shiew-Mei Huang, L. Lesko, Roger L. Williams, 2000, Journal of clinical pharmacology.

Relative bioavailability of commercially available ibuprofen oral dosage forms in humans.

K. Albert, W. Gillespie, A. Disanto, 1982, Journal of pharmaceutical sciences.

Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I

C. Margossian, W. Gillespie, Yi Zhang, 2021, CPT: pharmacometrics & systems pharmacology.

Determination of flurbiprofen in human serum by reverse-phase high-performance liquid chromatography with fluorescence detection.

K. Albert, A. Raabe, W. Gillespie, 1984, Journal of pharmaceutical sciences.

Determination of ibuprofen in capillary and venous plasma by high-performance liquid chromatography with ultraviolet detection.

E. Antal, K. Albert, A. Raabe, 1984, Journal of pharmaceutical sciences.

Effects of age on the clinical pharmacokinetics of ibuprofen.

J. Wagner, K. Albert, W. Gillespie, 1984, The American journal of medicine.

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Klaus Romero, Marc R. Gastonguay, William R. Gillespie, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

Noncompartmental Versus Compartmental Modelling in Clinical Pharmacokinetics

W R Gillespie, W. Gillespie, 1991, Clinical pharmacokinetics.

Knowledge Sharing, and Training Are Critical for Future Success Pharmacometrics as a Discipline Is Entering the ''Industrialization'' Phase: Standards, Automation,

Hartmut Derendorf, Klaus Romero, Bernd Meibohm, 2010 .

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

T. Macgregor, H. Woerle, M. Gastonguay, 2014, British Journal of Clinical Pharmacology.

Effect of injection volume on the bioavailability of sterile medroxyprogesterone acetate suspension.

E. Antal, K. Albert, W. Gillespie, 1983, Clinical pharmacy.

A physiological and system analysis hybrid pharmacokinetic model to characterize carbon tetrachloride blood concentrations following administration in different oral vehicles

Hyo Jung Kim, J. Gallo, J. Bruckner, 1993, Journal of Pharmacokinetics and Biopharmaceutics.

Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography.

W. Gillespie, G. Stagni, 1995, Journal of chromatography. B, Biomedical applications.

New Mathematical Implementation of Generalized Pharmacodynamic Models: Method and Clinical Evaluation

A. Shepherd, W. Gillespie, G. Stagni, 1997, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships

J. Wagner, K. Albert, W. Gillespie, 1983, Clinical pharmacology and therapeutics.

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

B. Monz, J. Gross, A. Staab, 2013, BMJ Open.

Theoretical decrease in systemic availability with decrease in input rate at steady-state for first-pass drugs.

J. Wagner, E. Antal, K. Albert, 1985, Biopharmaceutics & drug disposition.

A method for evaluating the mean residence times of metabolites in the body, systemic circulation, and the peripheral tissue not requiring separate i.v. administration of metabolite.

P. Veng‐Pedersen, W. Gillespie, 1987, Biopharmaceutics & drug disposition.

A multidimensional deconvolution method for evaluating the absorption of drugs undergoing reversible metabolism and presystemic metabolite formation.

W. Gillespie, H. Cheng, 1993, Journal of pharmaceutical sciences.

Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success

Marc R Gastonguay, Hartmut Derendorf, Klaus Romero, 2010, Journal of clinical pharmacology.

The Effect of In Vivo Dissolution, Gastric Emptying Rate, and Intestinal Transit Time on the Peak Concentration and Area-Under-the-Curve of Drugs with Different Gastrointestinal Permeabilities

Ajaz S. Hussain, William R. Gillespie, Gordon L. Amidon, 2004, Pharmaceutical Research.

FDA Guidance for Industry 1 Extended Release Solid Oral Dosage forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations

Vinod P. Shah, Ajaz S. Hussain, William R. Gillespie, 1997 .

Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus

A. van Maurik, W. Gillespie, R. Dimelow, 2023, CPT: pharmacometrics & systems pharmacology.

Bayesian PBPK modeling using R/Stan/Torsten and Julia/SciML/Turing.Jl

Timothy D. Knab, Ahmed Elmokadem, W. Gillespie, 2023, CPT: Pharmacometrics & Systems Pharmacology.

Influence of route of administration on the pharmacokinetics of methylprednisolone

E. Antal, K. Albert, W. Gillespie, 1983, Journal of Pharmacokinetics and Biopharmaceutics.

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

L. Gibiansky, S. Girish, D. Lu, 2015 .

Convolution-based approaches for in vivo-in vitro correlation modeling.

W R Gillespie, W. Gillespie, William R. Gillespie, 1997, Advances in experimental medicine and biology.

Technical Appendix to : A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications : an example using DPP-4 inhibitors , sitagliptin and linagliptin , in treatment of type 2 diabetes mellitus December

B. Monz, J. Gross, A. Staab, 2012 .

Population pharmacokinetics in pediatric patients using bayesian approaches with informative prior distributions based on adults

W. Gillespie, K. Khoo, 1999 .

Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailahility and distribution time concepts applied to the evaluation of distribution kinetics

P. Veng‐Pedersen, W. Gillespie, 1987, Journal of Pharmacokinetics and Biopharmaceutics.

Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics

P. Veng‐Pedersen, W. Gillespie, 1985, Journal of Pharmacokinetics and Biopharmaceutics.

Chemical and Enzymatic Ketonization of 2-Hydroxymuconate, a Conjugated Enol.

C. P. Whitman, N. Stolowich, W. Gillespie, 1991 .

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

B. Corrigan, Sue-Jane Wang, T. Colatsky, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

A polyexponential deconvolution method. Evaluation of the “gastrointestinal bioavailability” and meanin vivo dissolution time of some ibuprofen dosage forms

Peter Veng-Pedersen, William R. Gillespie, P. Veng‐Pedersen, 1985, Journal of Pharmacokinetics and Biopharmaceutics.

The determination of mean residence time using statistical moments:It is correct

P. Veng‐Pedersen, W. Gillespie, 1985, Journal of Pharmacokinetics and Biopharmaceutics.

Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

Kaori Ito, B. Corrigan, K. Romero, 2012, Journal of Pharmacokinetics and Pharmacodynamics.

A model of fracture risk used to examine the link between bone mineral density and the impact of different therapeutic mechanisms on fracture outcomes in patients with osteoporosis

M. Gastonguay, M. Riggs, W. Gillespie, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Commentary on “physiologically based pharmacokinetic modeling as a tool for drug development”

Thomas M. Ludden, William R. Gillespie, T. Ludden, 1995, Journal of Pharmacokinetics and Biopharmaceutics.

A system approach to pharmacodynamics. I: Theoretical framework.

P. Veng‐Pedersen, W. Gillespie, 1988, Journal of pharmaceutical sciences.

Ibuprofen and acetaminophen kinetics when taken concurrently

E. Antal, K. Albert, W. Gillespie, 1983, Clinical pharmacology and therapeutics.

Truncated sigmoid Emax model for use with truncated PK/PD aata

W. Gillespie, W. J. Bachman, 1998 .